OGXI Disappoints, CHMA Hands Out Pink Slips Again, No Issues For ANTH's Solution

Shares of OncoGenex Pharmaceuticals Inc. (OGXI) slumped over 41% on Tuesday as the company's phase III trial of Custirsen in men with metastatic castrate-resistant prostate cancer failed to meet the primary endpoint.

from RTT - Biotech http://ift.tt/2bm79d0
via IFTTT